Exploring Eye Vergence Markers ADHD) and ASD
Launched by ELIZABETH KILBEY · Mar 12, 2025
Trial Information
Current as of April 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how eye movements, specifically eye vergence (which helps us see in 3D), might be linked to attention in children and adults with Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). Researchers are using computer-based eye-tracking tasks to see how well these eye movements can help identify different types of attention problems. They hope that by understanding the relationship between eye vergence and attention, they can help detect attention issues earlier and provide better-targeted treatments.
To participate, individuals aged 6 and older are welcome, whether they have been diagnosed with ADHD or ASD or are part of a control group without these conditions. Participants will take part in eye-tracking tasks, and the study will also explore using smartphone cameras for tracking eye movements. It's important to note that individuals with certain vision issues, like uncorrected eyesight problems or other eye disorders, cannot participate. This research is focused on learning more about how attention works in people with ADHD and ASD, rather than testing a medical device for diagnosis or treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical Groups: Patients currently undergoing or who have previously undergone an assessment for either ADHD and/or Autism at either the CAN centre or Dr Kilbey's private practice in Beckenham.
- • Control Group: Subjects without a diagnosis of either ADHD nor Autism, who show no traits of these conditions.
- • People of any gender/sex who are aged older than 6 years old.
- Exclusion Criteria:
- • Those with non-corrected vision - e.g. near-sightedness, far-sightedness, strabismus or nystagmus
- • Individuals with any other oculomotor deficiency, blindness or vision loss.
About Elizabeth Kilbey
Elizabeth Kilbey is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in clinical development, she focuses on innovative therapies across various therapeutic areas, ensuring rigorous adherence to regulatory standards and ethical guidelines. Elizabeth’s collaborative approach fosters partnerships with research institutions and healthcare professionals, promoting the efficient design and execution of clinical trials. Her leadership is characterized by a passion for scientific excellence and a patient-centered perspective, driving the development of safe and effective treatments for unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, Catalonia, Spain
Beckenham, London, United Kingdom
New Malden, London, United Kingdom
Patients applied
Trial Officials
Hans A Super, BSc MSc PhD
Study Director
Braingaze & University of Barcelona
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported